Cerner Corporation Receives FDA Clearance for Mobile Fetal Monitoring Solution
Published: Nov 13, 2012
To solve this problem, Cerner (Nasdaq:CERN) developed Cerner FetaLink+™, a solution that provides clinicians access to maternal and fetal surveillance information via an iPad or iPhone, driving efficiency at the point of care. Cerner FetaLink+, which integrates with Cerner PowerChart Touch™, recently received 510(k) pre-market clearance from the U.S. Food and Drug Administration (FDA) and is now available in the United States and all U.S. territories.
Managing risk and ensuring a high level of care are critical in the maternal care setting. Cerner FetaLink+ allows clinicians to assess the status of patients by displaying the relationship of fetal and maternal waveforms, allowing clinicians to more easily analyze changes in waveform patterns over time. Additionally, clinicians can temporarily or permanently hide or display any waveforms. They can then analyze each waveform independently or in conjunction with waveforms of choice to support decision-making.
Clinicians can quickly view annotations on the fetal strip. The annotation summary offers clinicians a quick way to review a chronological order of vital signs and annotation entries. The summary also serves as a navigation tool for viewing a historical waveform at the correlating time of entry.
The Cerner FetaLink+ solution, along with Cerner FetaLink® and Cerner PowerChart Maternity™ solution, helps populate lifetime electronic health records for the mother and the baby, gathering data even before a baby is born. A fully integrated maternity solution benefits clinicians and their patients by:
Providing near real-time access to critical information about a woman's pregnancy and the health of her baby, improving patient safety and helping clinicians make informed decisions;
Creating mobile access to fetal and maternal waveform data and key pregnancy related data: EDD, EGA, cervical exam status, and gravida para.
Allowing clinicians to compare historical pregnancy data that can be used to evaluate the health of subsequent pregnancies; and
Reducing medical errors associated with illegible handwriting and transcription inaccuracies.
Cerner is contributing to the systemic change of health and care delivery. For more than 30 years Cerner has been executing its vision to make health care safer and more efficient. We started with the foundation of digitizing paper processes and now offer the most comprehensive array of information software, professional services, medical device integration, remote hosting and employer health and wellness services. Cerner systems are used by everyone from individual consumers, to single-doctor practices, hospitals, employers and entire countries. Taking what we've learned over more than three decades, Cerner is building on the knowledge that is in the system to support evidence-based clinical decisions, prevent medical errors and empower patients in their care.
Cerner® solutions are licensed by approximately 9,300 facilities around the world, including more than 2,650 hospitals; 3,750 physician practices; 40,000 physicians; 500 ambulatory facilities, such as laboratories, ambulatory centers, cardiac facilities, radiology clinics and surgery centers; 800 home health facilities; 40 employer sites and 1,600 retail pharmacies.
Certain trademarks, service marks and logos (collectively, the "Marks") set forth herein are owned by Cerner Corporation and/or its subsidiaries in the United States and certain other countries throughout the world. All other non-Cerner Marks are the property of their respective owners. Nasdaq: CERN. For more information about Cerner, please visit www.cerner.com, Twitter, Facebook and YouTube.
Media Contact: Megan Moriarty, (816) 888-2470
Investors Contact: Allan Kells, (816) 201-2445